Selected research
Industry Research
Mesalazine Enteric Coated Tablets Industry Research Report 2026
Market perspective
The global Mesalazine Enteric Coated Tablets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mesalazine Enteric Coated Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mesalazine Enteric Coated Tablets is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mesalazine Enteric Coated Tablets is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mesalazine Enteric Coated Tablets include CR Sanjiu, Huahai Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Fosun Pharma, DSM Pharmaceuticals, Dr. Falk Pharma GmbH, Astellas Pharma Inc. and AbbVie Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mesalazine Enteric Coated Tablets market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mesalazine Enteric Coated Tablets Market by Company
CR Sanjiu
Huahai Pharmaceuticals
UCB Pharma
Sun Pharmaceutical Industries Ltd.
Fosun Pharma
DSM Pharmaceuticals
Dr. Falk Pharma GmbH
Astellas Pharma Inc.
AbbVie Inc.
Mesalazine Enteric Coated Tablets Segment by Type
0.25g
0.5g
1g
Mesalazine Enteric Coated Tablets Segment by Application
Hospital
Clinic
Others
Mesalazine Enteric Coated Tablets Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesalazine Enteric Coated Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesalazine Enteric Coated Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesalazine Enteric Coated Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mesalazine Enteric Coated Tablets manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mesalazine Enteric Coated Tablets by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mesalazine Enteric Coated Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 0.25g
- 0.5g
- 1g
Applications
- Hospital
- Clinic
- Others
Companies covered
- CR Sanjiu
- Huahai Pharmaceuticals
- UCB Pharma
- Sun Pharmaceutical Industries Ltd.
- Fosun Pharma
- DSM Pharmaceuticals
- Dr. Falk Pharma GmbH
- Astellas Pharma Inc.
- AbbVie Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mesalazine Enteric Coated Tablets Market Size (2021-2032)
- 2.2.2 Global Mesalazine Enteric Coated Tablets Sales (2021-2032)
- 2.2.3 Global Mesalazine Enteric Coated Tablets Market Average Price (2021-2032)
- 2.3 Mesalazine Enteric Coated Tablets by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 0.25g
- 2.3.3 0.5g
- 2.3.4 1g
- 2.4 Mesalazine Enteric Coated Tablets by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mesalazine Enteric Coated Tablets Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mesalazine Enteric Coated Tablets Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Mesalazine Enteric Coated Tablets Revenue of Manufacturers (2021-2026)
- 3.4 Global Mesalazine Enteric Coated Tablets Average Price by Manufacturers (2021-2026)
- 3.5 Global Mesalazine Enteric Coated Tablets Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mesalazine Enteric Coated Tablets, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mesalazine Enteric Coated Tablets, Product Type & Application
- 3.8 Global Manufacturers of Mesalazine Enteric Coated Tablets, Established Date
- 3.9 Global Mesalazine Enteric Coated Tablets Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CR Sanjiu
- 4.1.1 CR Sanjiu Company Information
- 4.1.2 CR Sanjiu Business Overview
- 4.1.3 CR Sanjiu Mesalazine Enteric Coated Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CR Sanjiu Mesalazine Enteric Coated Tablets Product Portfolio
- 4.1.5 CR Sanjiu Recent Developments
- 4.2 Huahai Pharmaceuticals
- 4.2.1 Huahai Pharmaceuticals Company Information
- 4.2.2 Huahai Pharmaceuticals Business Overview
- 4.2.3 Huahai Pharmaceuticals Mesalazine Enteric Coated Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Huahai Pharmaceuticals Mesalazine Enteric Coated Tablets Product Portfolio
- 4.2.5 Huahai Pharmaceuticals Recent Developments
- 4.3 UCB Pharma
- 4.3.1 UCB Pharma Company Information
- 4.3.2 UCB Pharma Business Overview
- 4.3.3 UCB Pharma Mesalazine Enteric Coated Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 UCB Pharma Mesalazine Enteric Coated Tablets Product Portfolio
- 4.3.5 UCB Pharma Recent Developments
- 4.4 Sun Pharmaceutical Industries Ltd.
- 4.4.1 Sun Pharmaceutical Industries Ltd. Company Information
- 4.4.2 Sun Pharmaceutical Industries Ltd. Business Overview
- 4.4.3 Sun Pharmaceutical Industries Ltd. Mesalazine Enteric Coated Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sun Pharmaceutical Industries Ltd. Mesalazine Enteric Coated Tablets Product Portfolio
- 4.4.5 Sun Pharmaceutical Industries Ltd. Recent Developments
- 4.5 Fosun Pharma
- 4.5.1 Fosun Pharma Company Information
- 4.5.2 Fosun Pharma Business Overview
- 4.5.3 Fosun Pharma Mesalazine Enteric Coated Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Fosun Pharma Mesalazine Enteric Coated Tablets Product Portfolio
- 4.5.5 Fosun Pharma Recent Developments
- 4.6 DSM Pharmaceuticals
- 4.6.1 DSM Pharmaceuticals Company Information
- 4.6.2 DSM Pharmaceuticals Business Overview
- 4.6.3 DSM Pharmaceuticals Mesalazine Enteric Coated Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 DSM Pharmaceuticals Mesalazine Enteric Coated Tablets Product Portfolio
- 4.6.5 DSM Pharmaceuticals Recent Developments
- 4.7 Dr. Falk Pharma GmbH
- 4.7.1 Dr. Falk Pharma GmbH Company Information
- 4.7.2 Dr. Falk Pharma GmbH Business Overview
- 4.7.3 Dr. Falk Pharma GmbH Mesalazine Enteric Coated Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Dr. Falk Pharma GmbH Mesalazine Enteric Coated Tablets Product Portfolio
- 4.7.5 Dr. Falk Pharma GmbH Recent Developments
- 4.8 Astellas Pharma Inc.
- 4.8.1 Astellas Pharma Inc. Company Information
- 4.8.2 Astellas Pharma Inc. Business Overview
- 4.8.3 Astellas Pharma Inc. Mesalazine Enteric Coated Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Astellas Pharma Inc. Mesalazine Enteric Coated Tablets Product Portfolio
- 4.8.5 Astellas Pharma Inc. Recent Developments
- 4.9 AbbVie Inc.
- 4.9.1 AbbVie Inc. Company Information
- 4.9.2 AbbVie Inc. Business Overview
- 4.9.3 AbbVie Inc. Mesalazine Enteric Coated Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AbbVie Inc. Mesalazine Enteric Coated Tablets Product Portfolio
- 4.9.5 AbbVie Inc. Recent Developments
5 Global Mesalazine Enteric Coated Tablets Market Scenario by Region
- 5.1 Global Mesalazine Enteric Coated Tablets Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mesalazine Enteric Coated Tablets Sales by Region: 2021-2032
- 5.2.1 Global Mesalazine Enteric Coated Tablets Sales by Region: 2021-2026
- 5.2.2 Global Mesalazine Enteric Coated Tablets Sales by Region: 2027-2032
- 5.3 Global Mesalazine Enteric Coated Tablets Revenue by Region: 2021-2032
- 5.3.1 Global Mesalazine Enteric Coated Tablets Revenue by Region: 2021-2026
- 5.3.2 Global Mesalazine Enteric Coated Tablets Revenue by Region: 2027-2032
- 5.4 North America Mesalazine Enteric Coated Tablets Market Facts & Figures by Country
- 5.4.1 North America Mesalazine Enteric Coated Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mesalazine Enteric Coated Tablets Sales by Country (2021-2032)
- 5.4.3 North America Mesalazine Enteric Coated Tablets Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Mesalazine Enteric Coated Tablets Market Facts & Figures by Country
- 5.5.1 Europe Mesalazine Enteric Coated Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mesalazine Enteric Coated Tablets Sales by Country (2021-2032)
- 5.5.3 Europe Mesalazine Enteric Coated Tablets Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Mesalazine Enteric Coated Tablets Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mesalazine Enteric Coated Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mesalazine Enteric Coated Tablets Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mesalazine Enteric Coated Tablets Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mesalazine Enteric Coated Tablets Market Facts & Figures by Country
- 5.7.1 South America Mesalazine Enteric Coated Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mesalazine Enteric Coated Tablets Sales by Country (2021-2032)
- 5.7.3 South America Mesalazine Enteric Coated Tablets Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Mesalazine Enteric Coated Tablets Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mesalazine Enteric Coated Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mesalazine Enteric Coated Tablets Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mesalazine Enteric Coated Tablets Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Mesalazine Enteric Coated Tablets Sales by Type (2021-2032)
- 6.1.1 Global Mesalazine Enteric Coated Tablets Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Mesalazine Enteric Coated Tablets Sales Market Share by Type (2021-2032)
- 6.2 Global Mesalazine Enteric Coated Tablets Revenue by Type (2021-2032)
- 6.2.1 Global Mesalazine Enteric Coated Tablets Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Mesalazine Enteric Coated Tablets Revenue Market Share by Type (2021-2032)
- 6.3 Global Mesalazine Enteric Coated Tablets Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Mesalazine Enteric Coated Tablets Sales by Application (2021-2032)
- 7.1.1 Global Mesalazine Enteric Coated Tablets Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Mesalazine Enteric Coated Tablets Sales Market Share by Application (2021-2032)
- 7.2 Global Mesalazine Enteric Coated Tablets Revenue by Application (2021-2032)
- 7.2.1 Global Mesalazine Enteric Coated Tablets Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mesalazine Enteric Coated Tablets Revenue Market Share by Application (2021-2032)
- 7.3 Global Mesalazine Enteric Coated Tablets Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mesalazine Enteric Coated Tablets Value Chain Analysis
- 8.1.1 Mesalazine Enteric Coated Tablets Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mesalazine Enteric Coated Tablets Production Mode & Process
- 8.2 Mesalazine Enteric Coated Tablets Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mesalazine Enteric Coated Tablets Distributors
- 8.2.3 Mesalazine Enteric Coated Tablets Customers
9 Global Mesalazine Enteric Coated Tablets Analyzing Market Dynamics
- 9.1 Mesalazine Enteric Coated Tablets Industry Trends
- 9.2 Mesalazine Enteric Coated Tablets Industry Drivers
- 9.3 Mesalazine Enteric Coated Tablets Industry Opportunities and Challenges
- 9.4 Mesalazine Enteric Coated Tablets Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst